CAS: 120945-63-3; Hfpb

专利信息

专利号:US-2023398215-A1
优先权日:2020-10-28
标 题:Genetically engineered antigen-specific natural killer cells for in situ synthesis of proteins
发明人：BHATNAGAR PARIJAT
权利人:STANFORD RES INST INT
摘要:An example genetically engineered natural killer (NK) cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes a surface antigen of a target cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of the target cell, the engineered NK cell is configured to activate and, to synthesize and secrete the effector protein.

专利号:US-11672829-B2
优先权日:2015-09-10
标 题:Genetically engineered coronavirus-specific effector cells for in situ synthesis of antiviral proteins
发明人：BHATNAGAR PARIJAT; SSEMADAALI MARVIN A
权利人:STANFORD RES INST INT
摘要:An example genetically engineered effector cell comprises an exogenous polynucleotide sequence that includes a receptor element, an actuator element, and an effector element. The receptor element encodes a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain operably linked to a transmembrane domain, and an intracellular signaling domain, wherein the extracellular antigen binding domain recognizes an antigen on a surface of a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected cell. The actuator element encodes a transcription factor binding site that upregulates synthesis of an antiviral protein. The effector element encodes the antiviral protein operably linked to a signal peptide, wherein, in response to the antigen binding domain of the CAR binding to the antigen of SARS-CoV-2-infected cell, the engineered effector cell is configured to activate and, to synthesize and secrete the antiviral protein.

专利号:US-2024101632-A1
优先权日:2021-01-27
标 题:Genetically engineered electrically-stimulated effector cells for in situ synthesis of proteins
发明人：BHATNAGAR PARIJAT; NEWMYER SHERRI
权利人:STANFORD RES INST INT
摘要:An example genetically engineered electrically-stimulated (ES) cell comprises an exogenous polynucleotide sequence that includes an electrical-sensor element, an actuator element, and an effector element. The electrical-sensor element encodes a voltage-gated calcium ion channel (CaV), wherein the CaV is configured to transition from a closed state to an open state in response to stimulation. The actuator element encodes a transcription factor binding site that upregulates synthesis of an effector protein. The effector element encodes the effector protein, wherein, in response to the transition of the CaV to the open state, the genetically engineered ES effector cell is configured to activate and, to synthesize and secrete the effector protein.

专利号:WO-2024170500-A1
优先权日:2023-02-13
标题:Methods of treating iron deficiency-related diseases
发明人：KAUTZ LÉON
权利人:INST NAT SANTE RECH MED; ECOLE NAT VETERINAIRE DE TOULOUSE; INSTITUT NATIONAL DE RECH POUR L’AGRICULTURE L’ALIMENTATION ET L’ENVIRONNEMENT; UNIV TOULOUSE III – PAUL SABATIER
摘要:Anemia, defined as a decreased quantity of circulating functional red blood cells, is a major source of morbidity and mortality affecting a-third of the worldwide population. As a functional component of erythrocytes hemoglobin, iron is essential for oxygen storage and transport. The liver-derived peptide hepcidin is the master regulator of iron homeostasis. During anemia, the erythroid hormone erythroferrone regulates hepcidin synthesis to ensure the proper supply of iron to the bone marrow for red blood cells synthesis. However, mounting evidence suggested that another factor may exert a similar function. Inventors identified the hepatokine FGL1 as a previously undescribed suppressor of hepcidin that is highly induced in the liver in response to hypoxia during the recovery from anemia and in thalassemic mice. Inventors demonstrated that FGL1 is a potent suppressor of hepcidin in vitro and in vivo. Deletion of Fgl1 in mice results in a blunted repression of hepcidin after bleeding. Finally, FGL1 is a BMP antagonist that directly binds BMP6 to impair the canonical BMP-SMAD signaling cascade that governs hepcidin regulation. Accordingly, the present invention relates to a FGL1 polypeptide for use in the treatment of a patient affected with an iron deficiency-related disease.

专利号:WO-2022165079-A1
优先权日:2021-01-27
标 题 :Genetically engineered electrically-stimulated effector cells for in situ synthesis of proteins

专利号:EP-4580642-A2
优先权日:2022-09-01
标 题 :Genetically engineered cd4 t-cells for in situ synthesis of proteins